[1] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
[2] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009,360(23):2397-2405. doi: 10.1056/NEJMoa0808427.
URL
pmid: 19494215
|
[3] |
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014,371(8):723-732. doi: 10.1056/NEJMoa1313865.
URL
pmid: 25140958
|
[4] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469. doi: 10.3969/j.issn.1000-6621.2015.05.001.
|
[5] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
|
[6] |
World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization, 2013.
|
[7] |
中华医学会结核病学分会, 抗结核新药贝达喹啉临床应用专家共识编写组. 抗结核新药贝达喹啉临床应用专家共识. 中华结核和呼吸杂志, 2018,41(6):461-466. doi: 10.3760/cma.j.issn.1001-0939.2018.06.005.
|
[8] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[9] |
U.S.Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) [EB/OL]. [2021-01-21]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
|
[10] |
Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J, 2016,47(2):564-574. doi: 10.1183/13993003.00724-2015.
doi: 10.1183/13993003.00724-2015
URL
pmid: 26647431
|
[11] |
Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis, 2019,25(5):936-943. doi: 10.3201/eid2505.181823.
URL
pmid: 31002070
|
[12] |
Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis, 2015,60(2):188-194. doi: 10.1093/cid/ciu786.
doi: 10.1093/cid/ciu786
URL
pmid: 25320286
|
[13] |
World Health Organization. Report of the guideline development group meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis: a review of available evidence (2016). Geneva: World Health Organization, 2016.
|
[14] |
Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J, 2017,49(5):1700387. doi: 10.1183/13993003.00387-2017.
doi: 10.1183/13993003.00387-2017
URL
pmid: 28529205
|
[15] |
Yates TA. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis. Lancet Respir Med, 2018,6(12):e56. doi: 10.1016/S2213-2600(18)30453-3.
URL
pmid: 30629934
|
[16] |
Hewison C, Bastard M, Khachatryan N, et al. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. Int J Tuberc Lung Dis, 2018,22(7):766-772. doi: 10.5588/ijtld.17.0840.
URL
pmid: 29914602
|
[17] |
Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis, 2015,19(8):979-985. doi: 10.5588/ijtld.14.0944.
doi: 10.5588/ijtld.14.0944
URL
pmid: 26162365
|
[18] |
全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
|
[19] |
Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One, 2011,6(8):e23575. doi: 10.1371/journal.pone.0023575.
doi: 10.1371/journal.pone.0023575
URL
pmid: 21858172
|
[20] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2020: S1198-743X(20)30344-X. doi: 10.1016/j.cmi.2020.06.004.
URL
pmid: 33845206
|
[21] |
Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis, 2009,9(3):153-161. doi: 10.1016/S1473-3099(09)70041-6.
doi: 10.1016/S1473-3099(09)70041-6
URL
pmid: 19246019
|
[22] |
毛毅, 陈怡, 吴桂辉, 等. 肺结核患者营养风险与临床特征的相关性分析. 结核与肺部疾病杂志, 2020,1(1):24-28. doi: 10.3969/j.issn.2096-8493.2020.01.006.
|
[23] |
Jones J, Mudaly V, Voget J, et al. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. BMC Infect Dis, 2019,19(1):544. doi: 10.1186/s12879-019-4197-7.
URL
pmid: 31221100
|
[24] |
Lachenal N, Hewison C, Mitnick C, et al. Setting up pharmacovigilance based on available endTB Project data for bedaquiline. Int J Tuberc Lung Dis, 2020,24(10):1087-1094. doi: 10.5588/ijtld.20.0115.
URL
pmid: 33126944
|
[25] |
Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev, 2014,10(3):287-294. doi: 10.2174/1573403x10666140514103612.
URL
pmid: 24827793
|
[26] |
Sarin R, Vohra V, Singla N, et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J Tuberc, 2019,66(1):184-188. doi: 10.1016/j.ijtb.2019.02.006.
doi: 10.1016/j.ijtb.2019.02.006
URL
pmid: 30878066
|
[27] |
Kim JH, Kwon OJ, Kim YS, et al. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. Respir Investig, 2020,58(1):45-51. doi: 10.1016/j.resinv.2019.08.004.
doi: 10.1016/j.resinv.2019.08.004
URL
pmid: 31635903
|
[28] |
Mase S, Chorba T, Parks S, et al. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis, 2020,71(4):1010-1016. doi: 10.1093/cid/ciz914.
doi: 10.1093/cid/ciz914
URL
pmid: 31556947
|
[29] |
Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J, 2017,50(5):1701462. doi: 10.1183/13993003.01462-2017.
doi: 10.1183/13993003.01462-2017
URL
pmid: 29146605
|
[30] |
谢莉, 高静韬, 马丽萍, 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响. 中国防痨杂志, 2020,42(7):687-694. doi: 10.3969/j.issn.1000-6621.2020.07.009.
|
[31] |
Yoon HY, Jo KW, Nam GB, et al. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis, 2017,21(9):996-1001. doi: 10.5588/ijtld.17.0174.
doi: 10.5588/ijtld.17.0174
URL
pmid: 28826448
|